UNSPSC 51392305: Debrisoquine sulfate

This classification denotes an alpha-adrenergic blocking agent with the molecular formula 2C10H13N3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q94064N9NW, chemically known as 1,2,3, 4-tetrahydro-isoquinoline-2-carboxamidine sulfate but more generally known as debrisoquin sulfate, which bears US NIH Compound Identifier 2966. European Medicines Agency schedules Debrisoquine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01567MIG.

Most nations, for tariff and trade purposes, schedule debrisoquine sulfate under HS 29334990 and SITC 51575. SMILES: C1CCC2C(C1)CCN(C2)C(=N)N.C1CCC2C(C1)CCN(C2)C(=N)N.OS(=O)(=O)O.

UNSPSC 51392305 Debrisoquine sulfate is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceutical products and drug-intervention systems for community health and prescription-management programs. State and local governments soliciting under this code include county health departments and state health and human services agencies. Seminole County, Florida procures naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models to improve pharmacy benefit program efficiency. The work ranges from tactical supply procurement of specific medications and harm-reduction equipment to strategic market intelligence gathering on prescription-distribution channels and vendor capabilities for state-level program redesign.

Recent activity is concentrated in Florida and Texas. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with delivery to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription contracting models outside traditional pharmacy benefit manager and group purchasing organization arrangements. The Seminole County procurement requires e-procurement portal submission, drug-free workplace certification, E-Verify compliance, and maintains a two-year initial term with one-year renewal option; the Texas RFI is an exploratory phase preceding formal RFP development and does not commit to specific contract values or timelines.